Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma
Epistemonikos ID: 4db7f52c10d0f2b93916a81f094450d3e36de67b
First added on: May 21, 2024